Mint Venture Partners sees major returns as three portfolio companies list on KOSDAQ

Mint Venture Partners has announced significant investment returns following the KOSDAQ listings of three portfolio companies from its first fund, the ‘Mint Global Biotech Private Equity Partnership’.

The companies involved include AimedBio, which achieved a 23.1x return on investment; Mezoo, which saw a 9.1x return; and OrganoidScience, which recorded a 1.47x return. These successful exits have allowed the firm to recover its principal and standard returns five years after the fund's inception in 2021.

Beyond traditional investing, Mint Venture Partners operates a venture studio model, directly founding and nurturing startups by identifying promising technologies from universities and hospitals. Current ventures include Key Proteo, GenoTwin, ViewBrain Healthcare, and Lucera Healthcare. The firm plans to expand its focus into AI healthcare, drug development, diagnostics, and precision medicine through two new upcoming funds.